vs

Side-by-side financial comparison of Applied Therapeutics, Inc. (APLT) and Innventure, Inc. (INV). Click either name above to swap in a different company.

Applied Therapeutics, Inc. is the larger business by last-quarter revenue ($1.0M vs $822.0K, roughly 1.2× Innventure, Inc.). Applied Therapeutics, Inc. runs the higher net margin — -1899.0% vs -4593.8%, a 2694.8% gap on every dollar of revenue.

Relief Therapeutics is a Swiss biopharmaceutical company based in Geneva. The company focuses on developing drugs for serious diseases with few or no existing treatment options. Its lead compound, RLF-100, is a synthetic form of a natural peptide that protects the lung. The company was incorporated as Relief Therapeutics Holdings AG (RFLB.S) and listed on the SIX Swiss Exchange in 2016.

Innventure, Inc. is a business development and commercialization firm that partners with large global corporations to turn their underutilized intellectual property and unused R&D innovations into scalable, high-growth independent businesses. It focuses on sectors including sustainability, advanced materials and life sciences, serving primarily North American and European markets.

APLT vs INV — Head-to-Head

Bigger by revenue
APLT
APLT
1.2× larger
APLT
$1.0M
$822.0K
INV
Higher net margin
APLT
APLT
2694.8% more per $
APLT
-1899.0%
-4593.8%
INV

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
APLT
APLT
INV
INV
Revenue
$1.0M
$822.0K
Net Profit
$-19.0M
$-37.8M
Gross Margin
-1315.8%
Operating Margin
-1675.8%
-3859.1%
Net Margin
-1899.0%
-4593.8%
Revenue YoY
719.7%
Net Profit YoY
72.3%
EPS (diluted)
$-0.13
$-0.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
APLT
APLT
INV
INV
Q4 25
$822.0K
Q3 25
$1.0M
$534.0K
Q2 25
$0
$476.0K
Q1 25
$0
$224.0K
Q4 24
$-1.0K
Q3 24
$317.0K
Q2 24
$144.0K
Q1 24
$190.0K
Net Profit
APLT
APLT
INV
INV
Q4 25
$-37.8M
Q3 25
$-19.0M
$-28.3M
Q2 25
$-21.3M
$-84.2M
Q1 25
$-21.8M
$-143.0M
Q4 24
$44.0M
Q3 24
$-2.2M
Q2 24
$2.9M
Q1 24
$-83.9M
Gross Margin
APLT
APLT
INV
INV
Q4 25
-1315.8%
Q3 25
-676.6%
Q2 25
-501.1%
Q1 25
17.9%
Q4 24
Q3 24
-145.1%
Q2 24
Q1 24
Operating Margin
APLT
APLT
INV
INV
Q4 25
-3859.1%
Q3 25
-1675.8%
-5469.1%
Q2 25
-29952.5%
Q1 25
-116606.3%
Q4 24
3302300.0%
Q3 24
-4313.6%
Q2 24
-14194.4%
Q1 24
-11101.6%
Net Margin
APLT
APLT
INV
INV
Q4 25
-4593.8%
Q3 25
-1899.0%
-5305.6%
Q2 25
-17694.7%
Q1 25
-63837.9%
Q4 24
-4400700.0%
Q3 24
-697.5%
Q2 24
2012.5%
Q1 24
-44177.9%
EPS (diluted)
APLT
APLT
INV
INV
Q4 25
$-0.18
Q3 25
$-0.13
$-0.51
Q2 25
$-0.15
$-1.60
Q1 25
$-0.15
$-3.10
Q4 24
$0.52
Q3 24
$-0.94
Q2 24
$-0.13
Q1 24
$-0.67

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
APLT
APLT
INV
INV
Cash + ST InvestmentsLiquidity on hand
$11.9M
$60.4M
Total DebtLower is stronger
$8.3M
Stockholders' EquityBook value
$-561.0K
$204.2M
Total Assets
$34.4M
$599.2M
Debt / EquityLower = less leverage
0.04×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
APLT
APLT
INV
INV
Q4 25
$60.4M
Q3 25
$11.9M
$9.1M
Q2 25
$30.4M
$7.0M
Q1 25
$50.8M
Q4 24
$79.4M
Q3 24
Q2 24
$122.2M
Q1 24
$146.5M
Total Debt
APLT
APLT
INV
INV
Q4 25
$8.3M
Q3 25
$29.5M
Q2 25
$16.8M
Q1 25
$12.3M
Q4 24
Q3 24
$14.9M
Q2 24
Q1 24
Stockholders' Equity
APLT
APLT
INV
INV
Q4 25
$204.2M
Q3 25
$-561.0K
$190.8M
Q2 25
$17.4M
$218.6M
Q1 25
$36.7M
$261.5M
Q4 24
$57.0M
Q3 24
$-22.3M
Q2 24
$72.4M
Q1 24
$67.3M
Total Assets
APLT
APLT
INV
INV
Q4 25
$599.2M
Q3 25
$34.4M
$556.5M
Q2 25
$37.3M
$556.0M
Q1 25
$56.9M
$660.4M
Q4 24
$86.7M
Q3 24
$55.7M
Q2 24
$127.8M
Q1 24
$151.2M
Debt / Equity
APLT
APLT
INV
INV
Q4 25
0.04×
Q3 25
0.15×
Q2 25
0.08×
Q1 25
0.05×
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
APLT
APLT
INV
INV
Operating Cash FlowLast quarter
$-18.4M
$-80.7M
Free Cash FlowOCF − Capex
$-82.1M
FCF MarginFCF / Revenue
-9987.8%
Capex IntensityCapex / Revenue
172.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-139.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
APLT
APLT
INV
INV
Q4 25
$-80.7M
Q3 25
$-18.4M
$-19.6M
Q2 25
$-20.3M
$-22.1M
Q1 25
$-28.6M
$-14.7M
Q4 24
$-19.5M
Q3 24
Q2 24
$-22.6M
Q1 24
$-18.9M
Free Cash Flow
APLT
APLT
INV
INV
Q4 25
$-82.1M
Q3 25
$-20.0M
Q2 25
$-22.1M
Q1 25
$-15.6M
Q4 24
Q3 24
Q2 24
Q1 24
FCF Margin
APLT
APLT
INV
INV
Q4 25
-9987.8%
Q3 25
-3747.8%
Q2 25
-4637.2%
Q1 25
-6970.1%
Q4 24
Q3 24
Q2 24
Q1 24
Capex Intensity
APLT
APLT
INV
INV
Q4 25
172.4%
Q3 25
82.2%
Q2 25
3.2%
Q1 25
409.4%
Q4 24
Q3 24
Q2 24
Q1 24
Cash Conversion
APLT
APLT
INV
INV
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-0.44×
Q3 24
Q2 24
-7.80×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons